SORAFENIB News

SORAFENIB currently has 8 news articles, with 22 predicted indications.

This page combines the AI-predicted indications for SORAFENIB with the latest health news. Indications highlighted in orange have recent news coverage.

Drug Information

Evidence level: L5
Predicted indications (22):
- renal cell adenocarcinoma (99.0%)
- adenocarcinoma of liver and intrahepatic biliary tract (99.0%)
- liver cancer (99.0%)
- squamous cell carcinoma of liver and intrahepatic biliary tract (99.0%)
- renal cell carcinoma (disease) (99.0%)
- pediatric hepatocellular carcinoma (99.0%)
- hepatocellular carcinoma (99.0%)
- clear cell renal carcinoma (99.0%)
- fibrolamellar hepatocellular carcinoma (99.0%)
- thyroid gland carcinoma (99.0%)
- undifferentiated carcinoma of liver and intrahepatic biliary tract (99.0%)
- nonpapillary renal cell carcinoma (99.0%)
- liposarcoma (99.8%)
- ovarian myxoid liposarcoma (99.8%)
- renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions (99.7%)
- renal cell carcinoma associated with neuroblastoma (99.7%)
- unclassified renal cell carcinoma (99.7%)
- childhood kidney cell carcinoma (99.6%)
- female breast carcinoma (99.5%)
- renal pelvis carcinoma (99.4%)
- vulva sarcoma (99.4%)
- dermatofibrosarcoma protuberans (99.3%)